Connect Biopharma Holdings Limited - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CNTB Nasdaq 2836 www.connectbiopharm.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Connect Biopharma Holdings Limited

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 - May 21st, 2026 10:05 pm
Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky - May 15th, 2026 7:40 am
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference - May 12th, 2026 2:05 pm
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 7:00 am
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis - Apr 23rd, 2026 7:00 am
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Apr 7th, 2026 9:00 am
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - Mar 31st, 2026 2:05 pm
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - Mar 30th, 2026 8:11 am
Connect Biopharma Announces $20.2 Million Private Placement Financing - Mar 30th, 2026 5:02 am
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - Mar 30th, 2026 5:01 am
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Mar 30th, 2026 5:00 am
Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts - Mar 14th, 2026 8:15 am
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Mar 10th, 2026 7:00 am
Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference - Mar 3rd, 2026 7:00 am
Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference - Feb 27th, 2026 4:46 am
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Feb 19th, 2026 7:00 am
3 Promising Penny Stocks With Market Caps Up To $400M - Jan 21st, 2026 11:05 am
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 - Jan 12th, 2026 6:00 am
Discovering Connect Biopharma Holdings And 2 Other Promising Penny Stocks - Dec 23rd, 2025 5:04 am
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, individual investors own 22% - Dec 16th, 2025 3:00 am